A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins

Affiliations

• ¹ Certara QSP, Certara UK Limited, Sheffield, UK.
• ² BioMedicine Design, Pfizer, Andover, Massachusetts, USA.
• ³ AbbVie Inc, North Chicago, Illinois, USA.
• ⁴ Pharmacometrics JP, Clinical Pharmacology and Exploratory Development, Astellas Pharma Inc., Tokyo, Japan.
• ⁵ Analysis & Pharmacokinetics Research Labs, Astellas Pharma Inc., Tsukuba-shi, Japan.
• ⁶ Pharmacometrics US, Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.
• ⁷ Bristol-Myers Squibb, Princeton, New Jersey, USA.
• ⁸ Certara QSP, Certara UK Limited, Canterbury, UK.
• ⁹ Development Sciences, Genentech, San Francisco, California, USA.
• ¹⁰ AME Biotechnology Discovery Research, Lilly Biotechnology Center, San Diego, California, USA.
• ¹¹ Eli Lilly and Company, Indianapolis, Indiana, USA.
• ¹² Eli Lilly Research & Development, Windlesham, UK.
• ¹³ BioMedicine Design, Pfizer, Cambridge, Massachusetts, USA.
• ¹⁴ Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.